SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-16-011603
Filing Date
2016-03-25
Accepted
2016-03-25 16:37:35
Documents
5
Period of Report
2016-05-03
Effectiveness Date
2016-03-25

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2227981zdef14a.htm DEF 14A 619286
2 G548486.JPG g548486.jpg GRAPHIC 17173
3 G971103.JPG g971103.jpg GRAPHIC 4111
4 G21592BGI001.GIF g21592bgi001.gif GRAPHIC 107922
5 G21592BGI002.GIF g21592bgi002.gif GRAPHIC 45702
  Complete submission text file 0001047469-16-011603.txt   861704
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36033 | Film No.: 161529990
SIC: 2834 Pharmaceutical Preparations